Young Chen
About Young Chen
Young Chen is a Principal Research Scientist at Bristol Myers Squibb with over 15 years of experience in the pharmaceutical industry, specializing in organic chemistry and drug discovery.
Current Roles at Bristol Myers Squibb and Quanticel Pharmaceuticals
Young Chen currently serves as Principal Research Scientist at Bristol Myers Squibb in San Diego, California. Concurrently, Chen holds the position of Senior Scientist at Quanticel Pharmaceuticals, also located in the Greater San Diego Area. These roles involve leading research projects and contributing to drug discovery and development within the pharmaceutical industry.
Previous Role at Takeda San Diego, Inc.
From 2006 to 2012, Young Chen worked at Takeda San Diego, Inc. as Scientist II. During this six-year period, Chen was involved in significant research projects that contributed to the company's research pipeline. This experience helped lay the foundation for a career in the pharmaceutical industry, focusing on organic chemistry and drug discovery.
Educational Background in Chemistry
Young Chen completed a Ph.D. in Chemistry at the University of Pennsylvania from 1999 to 2004. Following this, Chen pursued further specialization by studying Organic Chemistry at the California Institute of Technology, where an NIH Post Doctoral Fellowship was achieved between 2004 and 2006. This robust educational background has played a crucial role in shaping Chen's expertise in the field.
Experience and Specialization in Pharmaceutical Research
With over 15 years of experience in the pharmaceutical industry, Young Chen specializes in organic chemistry with a particular focus on drug discovery and development. Chen's expertise is supported by experience in both academic and industrial research settings, contributing to a comprehensive understanding of the field.
Tenure at Celgene
In October 2015, Young Chen joined Celgene as a Principal Research Scientist. This role involved leading and contributing to various research initiatives within the company, further demonstrating expertise in the pharmaceutical industry and commitment to advancing drug discovery efforts.